Table 1.
Baseline characteristics
| Characteristic | Quartile | P-value | |||
|---|---|---|---|---|---|
|
| |||||
| 1 (n=232) | 2 (n=231) | 3 (n=231) | 4 (n=230) | ||
| Age (yr) | 46.3±12.2 | 46.4±12.1 | 47.3±12.3 | 47.4±12.8 | 0.658 |
| Male sex | 126 (54.3) | 128 (55.4) | 152 (65.8) | 164 (71.3) | <0.001 |
| Body mass index (kg/m2) | 21.5±3.0 | 22.3±3.2 | 22.7±3.5 | 22.8±13.3 | <0.001 |
| Follow-up duration after KT (mo) | 89.4±40.9 | 81.9±50.0 | 84.5±44.5 | 84.9±40.6 | 0.339 |
| Dialysis vintage before KT (mo) | 12.0 (0.0–62.8) | 13.0 (0.0–72.1) | 24.5 (1.3–90.0) | 17.4 (0.0–87.2) | 0.051 |
| Primary renal disease | 0.261 | ||||
| Glomerulonephritis | 143 (61.6) | 132 (57.1) | 125 (54.1) | 119 (51.7) | |
| Diabetes | 51 (22.0) | 71 (30.7) | 74 (32.0) | 73 (31.7) | |
| Hypertension | 17 (7.3) | 12 (5.2) | 18 (7.8) | 17 (7.4) | |
| Other | 21 (9.1) | 16 (6.9) | 14 (6.1) | 21 (9.1) | |
| Comorbid conditions | |||||
| Hypertension | 194 (83.6) | 193 (83.5) | 192 (83.1) | 176 (76.5) | 0.136 |
| Diabetes | 59 (25.4) | 81 (35.1) | 82 (35.5) | 79 (34.3) | 0.064 |
| Number of HLA mismatches | 3.2±1.6 | 3.2±1.6 | 3.1±1.7 | 3.0±1.8 | 0.402 |
| Number of HLA-DR mismatches | 1.1±0.7 | 1.0±0.7 | 1.1±0.7 | 1.0±0.7 | 0.675 |
| Desensitization | 37 (15.9) | 39 (16.9) | 34 (14.7) | 30 (13.0) | 0.686 |
| Induction immunosuppressant | 0.511 | ||||
| Anti-thymocyte globulin | 13 (5.6) | 17 (7.4) | 10 (4.3) | 16 (7.0) | |
| Basiliximab | 219 (94.4) | 214 (92.6) | 221 (95.7) | 214 (93.0) | |
| Donor age (yr) | 46.4±13.7 | 46.8±13.3 | 47.3±14.6 | 45.9±13.0 | 0.748 |
| Donor sex (male) | 121 (52.6) | 116 (50.2) | 126 (55.5) | 125 (54.6) | 0.678 |
| Donor body mass index (kg/m2) | 23.1±3.3 | 23.6±3.4 | 23.7±3.2 | 23.8±3.4 | 0.158 |
| Donor type | 0.001 | ||||
| Living | 150 (64.7) | 166 (71.9) | 132 (57.1) | 129 (56.1) | |
| Deceased | 82 (35.3) | 65 (28.1) | 99 (42.9) | 101 (43.9) | |
| Laboratory finding | |||||
| WBC count (×109/L) | 5.56 (4.50–7.28) | 6.07 (4.93–7.79) | 6.18 (4.67–7.39) | 6.43 (5.06–8.09) | <0.001 |
| Neutrophil count (×109/L) | 3.53 (2.63–4.93) | 3.88 (3.05–5.42) | 3.75 (2.78–5.18) | 4.19 (3.22–5.56) | 0.002 |
| Lymphocyte count (×109/L) | 1.18 (0.86–1.53) | 1.17 (0.91–1.62) | 1.25 (0.93–1.59) | 1.27 (0.95–1.68) | 0.201 |
| Hemoglobin (g/dL) | 10.4 (9.3–11.4) | 10.9 (9.5–11.9) | 10.7 (9.5–11.9) | 10.4 (9.2–11.6) | 0.015 |
| Platelet count (×109/L) | 173.0 (134.5–212.5) | 182.0 (147.0–228.0) | 189.0 (147.0–236.0) | 198.0 (157.0–250.3) | <0.001 |
| Sodium (mEq/L) | 138.0 (136.0–141.0) | 138.0 (136.0–140.0) | 138.0 (135.0–140.0) | 137.0 (135.0–139.0) | 0.058 |
| Potassium (mEq/L) | 4.6±0.8 | 4.5±0.8 | 4.6±0.8 | 4.5±0.9 | 0.101 |
| Calcium (mg/dL) | 8.7 (8.1–9.4) | 8.9 (8.1–9.4) | 8.8 (8.2–9.5) | 8.8 (8.1–9.4) | 0.679 |
| Phosphate (mg/dL) | 4.7 (3.9–5.7) | 4.8 (3.9–5.9) | 4.9 (3.9–6.0) | 5.1 (3.9–6.1) | 0.618 |
| Uric acid (mg/dL) | 5.0 (4.0–7.2) | 4.6 (3.5–6.4) | 5.3 (4.0–6.7) | 5.4 (4.0–6.6) | 0.010 |
| Total cholesterol (mg/dL) | 155.7±39.5 | 157.9±42.6 | 152.4±44.1 | 154.0±44.9 | 0.905 |
| LDL cholesterol (mg/dL) | 96.5±33.4 | 93.9±32.1 | 91.9±36.7 | 82.9±25.7 | 0.027 |
| CRP (mg/dL) | 0.02 (0.01–0.04) | 0.08 (0.06–0.10) | 0.16 (0.12–0.22) | 0.53 (0.29–1.08) | <0.001 |
| Albumin (g/dL) | 4.1 (3.8–4.5) | 4.2 (3.7–4.5) | 4.0 (3.5–4.4) | 3.7 (3.3–4.2) | <0.001 |
| CAR | 0.60 (0.31–0.91) | 1.88 (1.49–2.27) | 4.19 (3.13–5.73) | 13.48 (8.53–30.26) | <0.001 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range). Quartile groups were established by dividing patients based on pretransplant CAR values.
KT, kidney transplantation; HLA, human leukocyte antigen; WBC, white blood cells; LDL, low-density lipoprotein; CRP, C-reactive protein; CAR, C-reactive protein-to-albumin ratio.